Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. [electronic resource]
Producer: 20130806Description: 4655-62 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- blood
- Azacitidine -- administration & dosage
- Feasibility Studies
- Female
- Follow-Up Studies
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Recurrence, Local -- drug therapy
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Prognosis
- Remission Induction
- Sorafenib
- Survival Rate
- Tandem Repeat Sequences -- genetics
- Young Adult
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.